About this Journal Submit a Manuscript Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 202497, 12 pages
http://dx.doi.org/10.1155/2013/202497
Research Article

Prediction of Clinically Relevant Safety Signals of Nephrotoxicity through Plasma Metabolite Profiling

1PharmPoint Consulting, Poolesville, MD 20837, USA
2BASF SE, Experimental Toxicology and Ecology, Z 470, D-67056 Ludwigshafen, Germany
3Metanomics GmbH, Tegeler Weg 33, 10589 Berlin, Germany
4Drug Safety Research Laboratories, Astellas Pharma Inc., Osaka, Japan
5AstraZeneca R&D, Innovative Medicines Personalised Healthcare & Biomarkers, Science for Life Laboratory, Box 1031, 17121 Solna, Sweden
6Pfizer R&D, Compound Safety Prediction, Groton, CT 06340, USA
7Drug Safety Executive Council, Needham, MA 02494, USA
8Metanomics Health GmbH, Tegeler Weg 33, 10589 Berlin, Germany
9Analytical and Bioanalytical Development, Bristol-Myers Squibb, Princeton, NJ 08543, USA

Received 23 January 2013; Revised 23 April 2013; Accepted 25 April 2013

Academic Editor: Tzung-Hai Yen

Copyright © 2013 W. B. Mattes et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Supplementary Material

Supplementary Figures provide the detailed Pattern Ranking results for cyclosporin A, doxorubicin, captopril and lisinopril, while Supplementary Table 1 provides the measured metabolites and their fold changes for all treatment groups.

  1. Supplementary Materials